Partnership? Buy-Out? FDA Negotiating & Encouragin
Post# of 148278
The share price movement has been rather consistent, a pattern has emerged.
Some think Market Makers or a Hedge Fund may be the main player(s) shorting CYDY, and....doing this in order to keep the price low during negotiations for a "Partnership". Some believe that a big pharma company can influence a hedge fund or market maker or that a big pharma company may have influence upon the FDA.
Even if there is no influence upon the FDA, it makes sense that the FDA could be concerned about a 12 employee, small no revenue ever, biotech being able to efficiently handle the upcoming demand for LL for s/c and longhaulers, probably also m/m cv19, then HIV and maybe breast cancer, NASH. So the FDA (maybe) wants the deal to be, EUA comes with a partnership with Lilly or ABBV or? to assure success on a grand scale.
Some say Nader is holding strong, he wants all the profit for Cytodyn. But the FDA may possibly withhold any EUA without a partnership with a big pharma company, to give the FDA confidence in LL having a big impact on disease.